PDT Partners’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.77M | Sell |
160,058
-35,107
| -18% | -$608K | 0.16% | 228 |
|
|
2025
Q1 | $4.27M | Buy |
195,165
+57,471
| +42% | +$1.26M | 0.3% | 93 |
|
|
2024
Q4 | $4.39M | Sell |
137,694
-7,825
| -5% | -$250K | 0.39% | 56 |
|
|
2024
Q3 | $4.2M | Buy |
145,519
+52,663
| +57% | +$1.52M | 0.37% | 49 |
|
|
2024
Q2 | $3.56M | Buy |
92,856
+36,335
| +64% | +$1.39M | 0.34% | 80 |
|
|
2024
Q1 | $3.32M | Buy |
56,521
+4,570
| +9% | +$269K | 0.31% | 93 |
|
|
2023
Q4 | $3.11M | Sell |
51,951
-13,575
| -21% | -$813K | 0.34% | 75 |
|
|
2023
Q3 | $2.49M | Buy |
65,526
+40,416
| +161% | +$1.54M | 0.31% | 99 |
|
|
2023
Q2 | $2.29M | Buy |
25,110
+8,286
| +49% | +$755K | 0.31% | 100 |
|
|
2023
Q1 | $1.11M | Buy |
+16,824
| New | +$1.11M | 0.15% | 235 |
|
|
2022
Q4 | – | Sell |
-37,504
| Closed | -$2.56M | – | 630 |
|
|
2022
Q3 | $2.56M | Sell |
37,504
-23,390
| -38% | -$1.6M | 0.39% | 37 |
|
|
2022
Q2 | $2.75M | Buy |
+60,894
| New | +$2.75M | 0.24% | 102 |
|
|
2020
Q1 | – | Sell |
-80,017
| Closed | -$2.45M | – | 659 |
|
|
2019
Q4 | $2.45M | Buy |
80,017
+32,415
| +68% | +$992K | 0.15% | 174 |
|
|
2019
Q3 | $1.15M | Buy |
47,602
+10,682
| +29% | +$257K | 0.07% | 266 |
|
|
2019
Q2 | $936K | Buy |
36,920
+8,520
| +30% | +$216K | 0.06% | 259 |
|
|
2019
Q1 | $554K | Buy |
+28,400
| New | +$554K | 0.03% | 308 |
|